Moderna Announces Interim Phase 3 Safety and Immunogenicity Results for mRNA-1010, a Seasonal Influenza Vaccine CandidateAccesswire • 02/16/23
The 10 Biggest Companies Reporting Earnings in the Fourth Week of February 202324/7 Wall Street • 02/16/23
Moderna CEO Stephane Bancel will testify before Senate next month on Covid vaccine price hikeCNBC • 02/15/23
Is Moderna Stock A Buy As It Faces Off With Pfizer, GSK In The Massive RSV Market?Investors Business Daily • 02/15/23
Here are five companies to pick if Goldman Sachs is right about the stock market being flat in 2023Market Watch • 02/13/23
Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical TrialsBusiness Wire • 02/03/23
Moderna to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 23, 2023Accesswire • 02/02/23
This Discount Growth Stock Is a Once-in-a-Decade Buying Opportunity Right NowThe Motley Fool • 01/31/23
Moderna's stock is down as Pfizer lowers revenue estimates for its COVID vaccine for 2023Market Watch • 01/31/23
Moderna (MRNA) RSV Jab For Older Adults Gets FDA Breakthrough TagZacks Investment Research • 01/31/23
The RSV Vaccine Battle Wages On With Moderna Scoring A Win Vs. Pfizer, GSKInvestors Business Daily • 01/30/23